# Safety Study of ALG- 1001 to Treat Diabetic Macular Edema

> **NCT01482871** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Allegro Ophthalmics, LLC**

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** ALG-1001
- **DRUG:** ALG-1001
- **DRUG:** ALG-1001
- **DRUG:** ALG-1001

## Key facts

- **NCT ID:** NCT01482871
- **Lead sponsor:** Allegro Ophthalmics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-01
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482871, "Safety Study of ALG- 1001 to Treat Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01482871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*